Altamirano J, Levis B, Markarian C, Cochran Q, Sherman C, Toeque M-G, Armas L, Sridhar G, Vannappagari V, Brown K, Fusco JS. Characteristics of Women Initiating CAB+RPV LA in the OPERA Cohort. IDWeek. Los Angeles, CA, USA; October 16-19, 2024
Research Category: Abstracts and Posters
Before and After Study of Hepatitis C Risk Score Alerts in CHORUS
Dieterich D, Palmieri Weber R, Hsu R, Millner C, Fusco J, Son A, Kreter B, Stepp A, Ye Q, Fusco G. Hepatitis C Screening: Before and After Study of Hepatitis C Risk Score Alerts in CHORUS. IDWeek. Los Angeles; October 16-19, 2024
Need for Increased HIV Testing Prior to and During Pre-Exposure Prophylaxis with Cabotegravir Long-Acting Injections in Routine Clinical Care in the United States
Hsu R, Brunet L, Mills A, Mounzer K, Wohlfeiler M, Frost K, Pierone G, Sension M, Lackey P, Fusco J, Brown C, Vannappagari V, Aboud M, Budnik P, Fusco G. Need for Increased HIV Testing Prior to and During Pre-Exposure Prophylaxis with Cabotegravir Long-Acting Injections in Routine Clinical Care in the United States. 25th International AIDS Conference. Munich, Germany; July 22-26, 2024
Increased Screening for Sexually Transmitted Infections and HIV Surrogate Marker Testing Among Long-Acting Injectable Versus Daily Oral Antiretroviral Therapy Users in the OPERA® Cohort
Lackey PC, Palmieri Weber R, Pierone Jr. G, Sension M, Mills A, Wohlfeiler MB, Fusco JS, Levis B, Sridhar G, Vannappagari V, van Wyk J, Fusco GP. Increased Screening for Sexually Transmitted Infections and HIV Surrogate Marker Testing Among Long-Acting Injectable Versus Daily Oral Antiretroviral Therapy Users in the OPERA® Cohort. 25th International AIDS Conference Munich; July 22-26, 2024.
Tenofovir disoproxil fumarate and tenofovir alafenamide interruption in hepatitis B and human immunodeficiency virus co-infected individuals in the United States: monitoring practices and incidence of hepatitis B reactivation or hepatitis flare
Dieterich DT, Brunet L, Hsu RK, Mounzer K, Pierone G, Wohlfeiler MB, Fusco JS, Dunbar MS, Gruber J, Yee LJ, Frenette C, Fusco GP. Tenofovir disoproxil fumarate and tenofovir alafenamide interruption in hepatitis B and human immunodeficiency virus co-infected individuals in the United States: monitoring practices and incidence of hepatitis B reactivation or hepatitis flare. European Association for the Study of the Liver Congress (EASL); June 5-8, 2024.
Moving More People with a Hepatitis C Diagnosis to Treatment: Alerts in CHORUS, a Clinical Decision Support System
Dieterich DT, Weber RP, Hsu RK, Millner C, Levis B, Osterman MD, Fusco JS, Son A, Kreter B, Fusco GP. Moving More People with a Hepatitis C Diagnosis to Treatment: Alerts in CHORUS, a Clinical Decision Support System. ACTHIV. Atlanta, Georgia, USA; 2024
Antiretroviral Therapy Experience of Heavily Treatment-Experienced and Virologically Suppressed Treatment-Experienced People with HIV in the OPERA Cohort
Lackey PC, Osterman MD, Palmieri Weber R, Hsu RK, Mounzer K, Sension M, Wohlfeiler MB, Fusco JS, Levis B, Gruber J, Park S, Dunbar M, Fusco GP. Antiretroviral Therapy Experience of Heavily Treatment-Experienced and Virologically Suppressed Treatment-Experienced People with HIV in the OPERA Cohort. ACTHIV. Atlanta, Georgia, USA; 2024
Weight Change After Starting Doravirine among ART-Experienced Individuals in the US
Mounzer K, Brunet L, Sension M, Hsu RK, Fusco JS, Whiteside YO, Fusco GP. Weight Change After Starting Doravirine among ART-Experienced Individuals in the US. In: Conference on Retroviruses and Opportunistic Infections (CROI). Denver, Colorado, USA; 2024
Pre-Exposure Prophylaxis with Cabotegravir Long-Acting Injectable in the OPERA Cohort
Mills A, Brunet L, Mounzer K, Wohlfeiler MB, Frost KR, Hsu RK, Pierone G, Sension M, Lackey PC, Fusco JS, Brown C, Vannappagari V, Aboud M, Budnik P, Fusco G. Pre-Exposure Prophylaxis with Cabotegravir Long-Acting Injectable in the OPERA Cohort. In: Conference on Retroviruses and Opportunistic Infections (CROI). Denver, Colorado, USA; 2024
Real-World Effectiveness of Cabotegravir + Rilpivirine vs. Standard of Care Oral Regimens in the US
Hsu RK, Sension M, Fusco JS, Brunet L, Cochran Q, Sridhar G, Vannappagari V, Van Wyk J, Wohlfeiler M, Levis B, Fusco GP. Real-World Effectiveness of Cabotegravir + Rilpivirine vs. Standard of Care Oral Regimens in the US. In: Conference on Retroviruses and Opportunistic Infections (CROI). Denver, Colorado, USA; 2024